Bexarotene
- Generic Name
- Bexarotene
- Brand Names
- Targretin
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28O2
- CAS Number
- 153559-49-0
- Unique Ingredient Identifier
- A61RXM4375
Overview
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Background
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Indication
用于全身治疗无效的皮肤Ｔ细胞淋巴癌（CTCL）。
Associated Conditions
- Refractory Cutaneous T-cell Lymphoma
Clinical Trials
FDA Approved Products
Bexarotene
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:ORAL
Strength:75 mg in 1 1
Approved: 2020/11/11
NDC:0054-0399
Bexarotene
Manufacturer:AvKARE
Route:ORAL
Strength:75 mg in 1 1
Approved: 2023/04/14
NDC:42291-072
Bexarotene
Manufacturer:Upsher-Smith Laboratories, Inc.
Route:ORAL
Strength:75 mg in 1 1
Approved: 2017/06/01
NDC:0832-0285
Targretin
Manufacturer:Bausch Health US, LLC
Route:TOPICAL
Strength:1 g in 100 g
Approved: 2020/02/03
NDC:0187-5525
Targretin
Manufacturer:Bausch Health US, LLC
Route:ORAL
Strength:75 mg in 1 1
Approved: 2020/04/30
NDC:0187-5526
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath